GB9916018D0 - Chitosan-gelatin a microparticles - Google Patents

Chitosan-gelatin a microparticles

Info

Publication number
GB9916018D0
GB9916018D0 GBGB9916018.6A GB9916018A GB9916018D0 GB 9916018 D0 GB9916018 D0 GB 9916018D0 GB 9916018 A GB9916018 A GB 9916018A GB 9916018 D0 GB9916018 D0 GB 9916018D0
Authority
GB
United Kingdom
Prior art keywords
chitosan
gelatin
bioadhesive
microparticles
microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB9916018.6A
Other versions
GB2335357A (en
GB2335357B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Publication of GB9916018D0 publication Critical patent/GB9916018D0/en
Publication of GB2335357A publication Critical patent/GB2335357A/en
Application granted granted Critical
Publication of GB2335357B publication Critical patent/GB2335357B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A drug delivery composition for nasal administration is provided which comprises the antiviral agent ICAM-1 and a bioadhesive material. The bioadhesive material may be a chitosan solution, a liquid formulation comprising a polymeric material or a plurality of bioadhesive microspheres. The polymeric material is preferably gellan gum or alginate. The microspheres may comprise starch, chitosan, hyaluronic acid, or gelatin.
GB9916018A 1997-01-14 1998-01-14 Chitosan-gelatin a microparticles Expired - Fee Related GB2335357B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9700624.1A GB9700624D0 (en) 1997-01-14 1997-01-14 Drug delivery composition
PCT/GB1998/000108 WO1998030207A1 (en) 1997-01-14 1998-01-14 Chitosan-gelatin a microparticles

Publications (3)

Publication Number Publication Date
GB9916018D0 true GB9916018D0 (en) 1999-09-08
GB2335357A GB2335357A (en) 1999-09-22
GB2335357B GB2335357B (en) 2000-12-13

Family

ID=10805925

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9700624.1A Pending GB9700624D0 (en) 1997-01-14 1997-01-14 Drug delivery composition
GB9916018A Expired - Fee Related GB2335357B (en) 1997-01-14 1998-01-14 Chitosan-gelatin a microparticles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB9700624.1A Pending GB9700624D0 (en) 1997-01-14 1997-01-14 Drug delivery composition

Country Status (15)

Country Link
US (1) US6465626B1 (en)
EP (1) EP0952822B1 (en)
JP (1) JP2001508061A (en)
AT (1) ATE235889T1 (en)
AU (1) AU725460B2 (en)
CA (1) CA2275717C (en)
DE (1) DE69812887T2 (en)
DK (1) DK0952822T3 (en)
ES (1) ES2200306T3 (en)
GB (2) GB9700624D0 (en)
NO (1) NO993195L (en)
NZ (1) NZ335815A (en)
PT (1) PT952822E (en)
WO (1) WO1998030207A1 (en)
ZA (1) ZA98273B (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
AU3024399A (en) * 1998-04-03 1999-10-25 Bm Research A/S Controlled release composition
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
WO2000004876A2 (en) * 1998-07-23 2000-02-03 Johns Hopkins University School Of Medicine Controlled release of bioactive substances
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
ATE258777T1 (en) * 1999-07-02 2004-02-15 Cognis Iberia Sl MICRO CAPSULES - II
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
IT1318618B1 (en) * 2000-07-10 2003-08-27 A C R Applied Coating Res S A QUICK RELEASE BIOADHESIVE MICROSPHERES FOR SUBLINGUAL ADMINISTRATION OF ACTIVE INGREDIENTS.
ITMI20010347A1 (en) 2001-02-21 2002-08-21 Grisotech S A IMMUNOGLOBULIN AND POLYSACCHARID COMPLEXES FOR ORAL ABSORPTION ETRANS-MUCOSAL
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
EP1416916B1 (en) 2001-08-16 2007-10-17 Cmp Therapeutics Limited Chitin microparticles and their medical uses
EP1443944A1 (en) * 2001-11-12 2004-08-11 Johannes Reinmüller Pharmaceutical applications of hyaluronic acid preparations
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US6830556B2 (en) 2002-01-08 2004-12-14 Zimmer Orthopaedic Surgical Products, Inc. Debridement extension providing irrigation and mechanical scrubbing for removal of dead, devitalized, or contaminated tissue from a wound
AU2003207508A1 (en) * 2002-01-10 2003-07-30 Northeastern University Hybrid immobilized catalytic system with controlled permeability
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
ZA200508480B (en) * 2003-05-01 2007-05-30 Archimedes Dev Ltd Nasal administration of the LH-RH analog leuprolide
CN1835723B (en) * 2003-06-16 2011-06-22 洛马林达大学医学中心 Deployable multifunctional hemostatic agent
CN101239200A (en) * 2003-06-16 2008-08-13 洛马林达大学医学中心 Deployable multifunctional hemostatic agent
CA2529717C (en) * 2003-06-16 2013-04-02 Loma Linda University Medical Center Deployable hemostatic agent
GB0315632D0 (en) * 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
DE10332160A1 (en) * 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multiparticulate dosage form containing mucoadhesively formulated peptide or protein active substances, and a method for producing the dosage form
GB0328186D0 (en) 2003-12-05 2004-01-07 West Pharm Serv Drug Res Ltd Intranasal compositions
GB0329918D0 (en) 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
JP4694214B2 (en) * 2004-02-20 2011-06-08 ローム株式会社 Comparator, AD conversion circuit, semiconductor device, and imaging device
CA2557042C (en) 2004-02-23 2013-06-25 Loma Linda University Medical Center Hemostatic agent for topical and internal use
WO2005102292A1 (en) * 2004-03-23 2005-11-03 Lytone Enterprise, Inc. Chitosan embedded or encapsulated capsule
US7740883B2 (en) * 2004-03-28 2010-06-22 University Of Debrecen Nanoparticles from chitosan
CA2565236A1 (en) * 2004-05-06 2005-11-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
EP1758633B1 (en) * 2004-05-13 2015-03-18 Medtronic Vascular, Inc. Methods for compounding a therapeutic agent to the adventitia of a vessel
GB0416328D0 (en) * 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
WO2006016530A1 (en) 2004-08-10 2006-02-16 Translational Research, Ltd. Transnasal composition having immediate action and high absorbability
DE102004059792A1 (en) 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multiparticulate dosage form containing mucoadhesively formulated nucleic acid active ingredients, and a method for producing the dosage form
EP1824459A1 (en) * 2004-12-17 2007-08-29 Medipol S.A. Hydrophilic particles based on cationic chitosan derivatives
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
US8303972B2 (en) * 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
EP1877041A2 (en) * 2005-04-29 2008-01-16 Cubist Pharmaceuticals, Inc. Therapeutic compositions
JP2007006849A (en) * 2005-07-04 2007-01-18 Japan Science & Technology Agency Nucleic acid transfection agent consisting of 6-amino-6-deoxychitosan derivative
EP2034954B1 (en) * 2006-03-30 2019-02-20 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
CA2848653A1 (en) 2006-06-02 2007-12-13 Synedgen, Inc. Chitosan-lysine derivative compounds
JP2009541281A (en) 2006-06-20 2009-11-26 シーエムピー セラピューティクス リミテッド Compositions containing chitin microparticles and their medical use
US20080248508A1 (en) * 2006-08-17 2008-10-09 Shenda Baker Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) * 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8337817B2 (en) 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
GB0716907D0 (en) * 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
GB0722507D0 (en) * 2007-11-19 2007-12-27 Zhao Xiaobin Hyaluronic acid personal lubricant
DE102008059857A1 (en) * 2008-12-01 2010-06-02 Forschungsinstitut für Leder und Kunststoffbahnen gGmbH Composition, useful e.g. in molded body, medical technology and packaging for industrial purposes, and as cell growth promoting material and matrix material for cell culture, comprises gelatin, and polysaccharide derivatives, as additives
JP2012526726A (en) 2009-05-15 2012-11-01 株式会社新日本科学 Intranasal pharmaceutical composition with improved pharmacokinetics
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
US8623274B2 (en) 2009-11-25 2014-01-07 Loma Linda University Medical Center Chitosan-based hemostatic textile
GB201006218D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
PL2696846T3 (en) * 2011-04-11 2018-06-29 Vitux Group As Oral pharmaceutical dispersion compositions
US8968790B2 (en) * 2011-12-09 2015-03-03 Shaker A. Mousa Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
FR2991172A1 (en) * 2012-06-01 2013-12-06 Galderma Res & Dev TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING MICROCAPSULES
CN104507458B (en) 2012-06-20 2018-05-22 滑铁卢大学 Mucoadhesive nano particle delivery system
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
FI3562486T3 (en) 2016-12-31 2024-06-04 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CA3090457A1 (en) * 2018-02-26 2019-08-29 Shin Nippon Biomedical Laboratories, Ltd. Powder preparation, cartridge, and device
KR20210028192A (en) 2018-06-27 2021-03-11 바이오엑셀 테라퓨틱스 인코포레이티드 Film formulation containing dexmedetomidine and method for producing same
JP2022540706A (en) 2019-07-19 2022-09-16 バイオエクセル セラピューティクス，インコーポレイテッド Nonsedating Dexmedetomidine Treatment Regimens
CN112370437B (en) * 2020-10-20 2022-10-21 好医生药业集团有限公司 Amoxicillin capsule and preparation method thereof
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN118304423B (en) * 2023-05-25 2024-10-11 无锡市第二人民医院 Research on P4HA1 siRNA carried by multi-layer chitosan gelatin particles for treating brain glioma by inhibiting cell EMT

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226849A (en) 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
JPS6034925B2 (en) 1979-07-31 1985-08-12 帝人株式会社 Long-acting nasal preparation and its manufacturing method
CA1219201A (en) 1983-03-07 1987-03-17 Albert E. Chu Microorganism detection test
GB8712176D0 (en) 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
CA2004270A1 (en) 1988-12-29 1990-06-29 William R. Michael Perfume microcapsules for use in granular detergent compositions
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
BE1003677A3 (en) 1990-01-29 1992-05-19 Schacht Etienne PROCESS FOR THE PREPARATION OF AZOBEVATTENDE POLYMERS AND THEIR USE AS A drug delivery systems.
EP0454444A1 (en) 1990-04-24 1991-10-30 Nissan Chemical Industries Ltd. Glutarimide derivatives and herbicides
CA2042529C (en) * 1990-08-10 2002-07-30 Chokyun Rha Polysaccharide article and uses therefor
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon

Also Published As

Publication number Publication date
WO1998030207A1 (en) 1998-07-16
GB2335357A (en) 1999-09-22
DE69812887T2 (en) 2003-12-18
ZA98273B (en) 1999-07-13
CA2275717A1 (en) 1998-07-16
GB2335357B (en) 2000-12-13
NZ335815A (en) 2001-03-30
US6465626B1 (en) 2002-10-15
CA2275717C (en) 2007-09-11
NO993195D0 (en) 1999-06-28
PT952822E (en) 2003-08-29
ATE235889T1 (en) 2003-04-15
JP2001508061A (en) 2001-06-19
AU5568998A (en) 1998-08-03
AU725460B2 (en) 2000-10-12
GB9700624D0 (en) 1997-03-05
DK0952822T3 (en) 2003-07-21
ES2200306T3 (en) 2004-03-01
DE69812887D1 (en) 2003-05-08
EP0952822B1 (en) 2003-04-02
NO993195L (en) 1999-06-28
EP0952822A1 (en) 1999-11-03

Similar Documents

Publication Publication Date Title
GB2335357B (en) Chitosan-gelatin a microparticles
GB2305606A (en) Drug delivery composition for the nasal administration of antiviral agents
CA2067228A1 (en) Drug delivery system, method for preparing the same and use thereof
GB2341550A (en) Gastroretentive controlled release microspheres for improved drug delivery
CA2312710A1 (en) Sustained release formulation containing three different types of polymers and tablet formed therefrom
AU1535799A (en) Pharmaceutical hydrogel formulations, drug delivery devices and methods
AU4121297A (en) Galenic form with extended release of milnacipran
EP1244471A4 (en) Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
PL343829A1 (en) Adhesive microsphere drug delivery composition
DE69803940D1 (en) OPHTHALMIC COMPOSITION WITH EXTENDED RELEASE CONTAINING WATER-SOLUBLE MEDICINAL PRODUCTS
CA2222567A1 (en) High viscosity liquid controlled biologically active delivery system
ES2068762A1 (en) Coated microparticles with improved drug absorption.
HUP9904174A2 (en) Pharmaceutical composition for transdermic delivery
WO1999012549A3 (en) Controlled release microsphere delivery system
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
WO2003103637A3 (en) Modified release, multiple unit drug delivery systems
CA2311450A1 (en) Pharmaceutical aerosol compositions
EP0485840A3 (en) Pharmaceutical oral composition and coating agent containing a polysaccharide degradable in the colon
WO2003053413A3 (en) Sustained-release compositions
EP0571671B1 (en) A Pharmaceutical composition in powder form
ZA968762B (en) Derivatives of acid pyrazoles, their preparation process, their use as medicaments, their new use and the pharmaceutical compositions containing them.
CA2356306A1 (en) Sulfated phosphatidylinositols, their preparation and use
IL113359A (en) Polysaccharide drug delivery matrix and slow release pharmaceutical preparation containing it
HUT75711A (en) The use of dimeticone as a transport and carrier system and/or drug delivery system, and pharmaceutical compositions containing dimeticone
HUP9902681A2 (en) Controlled-release pharmaceutical tablet containing a carrier based on cross-linked amylose and hydroxypropylmethylcellulose

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20070114